Boston Trust Walden
CORT icon

Boston Trust Walden’s Corcept Therapeutics CORT Stock Holding History

Boston Trust Walden’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$27.2M Sell
235,673
-204,591
-46% -$22M 0.22% 156
2026
Q2 		$38.3M Sell
440,264
-22,342
-5% -$1.35M 0.29% 124
2026
Q1 		$18.6M Sell
462,606
-65,020
-12% -$2.43M 0.15% 183
2025
Q4 		$18.4M Sell
527,626
-34,635
-6% -$2.72M 0.14% 181
2025
Q3 		$46.7M Sell
562,261
-9,811
-2% -$710K 0.34% 118
2025
Q2 		$42M Sell
572,072
-12,728
-2% -$923K 0.3% 133
2025
Q1 		$66.8M Sell
584,800
-314,261
-35% -$19.1M 0.49% 70
2024
Q4 		$45.3M Sell
899,061
-614,914
-41% -$32.2M 0.32% 129
2024
Q3 		$70.1M Sell
1,513,975
-69,924
-4% -$2.48M 0.49% 71
2024
Q2 		$51.5M Sell
1,583,899
-251,194
-14% -$6.88M 0.38% 106
2024
Q1 		$46.2M Sell
1,835,093
-11,831
-0.6% -$280K 0.33% 123
2023
Q4 		$60M Buy
1,846,924
+19,877
+1% +$546K 0.45% 77
2023
Q3 		$49.8M Sell
1,827,047
-169,310
-8% -$4.9M 0.42% 82
2023
Q2 		$44.4M Buy
1,996,357
+77,178
+4% +$1.78M 0.36% 101
2023
Q1 		$41.6M Buy
1,919,179
+72,898
+4% +$1.6M 0.36% 101
2022
Q4 		$37.5M Buy
1,846,281
+487,962
+36% +$12.2M 0.33% 109
2022
Q3 		$34.8M Buy
1,358,319
+47,281
+4% +$1.27M 0.35% 104
2022
Q2 		$31.2M Buy
1,311,038
+12,226
+0.9% +$266K 0.29% 125
2022
Q1 		$29.2M Buy
1,298,812
+267,805
+26% +$5.7M 0.24% 146
2021
Q4 		$20.4M Sell
1,031,007
-30,838
-3% -$626K 0.16% 178
2021
Q3 		$20.9M Buy
1,061,845
+311,494
+42% +$6.52M 0.19% 168
2021
Q2 		$16.5M Sell
750,351
-20,214
-3% -$450K 0.15% 184
2021
Q1 		$18.3M Buy
770,565
+360,721
+88% +$9.6M 0.18% 172
2020
Q4 		$10.7M Buy
+409,844
New +$8.63M 0.11% 203

Other funds holding CORT

Parallel Advisors
Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Granite Investment Partners
Granite Investment Partners El Segundo, California $1.84B AUM 35.93% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.9B AUM 30.31% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Brown Capital Management
Brown Capital Management Baltimore, Maryland $527M AUM 33.67% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Boston Trust Walden's CORT Position: Q3 2026 in Review

Boston Trust Walden reduced its Corcept Therapeutics (CORT) stake by 46% in Q3 2026, selling an estimated $22M and leaving 235,673 shares worth $27.2M. The position accounts for 0.22% of the portfolio, ranked #156.

Boston Trust Walden first reported a position in CORT in Q4 2020 and has held it in 24 quarters since. The position peaked at $70.1M in Q3 2024. 178 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Boston Trust Walden held 235,673 shares of Corcept Therapeutics worth $27.2M as of Q3 2026.
  • Boston Trust Walden sold 204,591 Corcept Therapeutics shares in Q3 2026, an estimated $22M.
  • Corcept Therapeutics made up 0.22% of Boston Trust Walden's portfolio in Q3 2026, its #156 holding.
  • Boston Trust Walden first reported a position in Corcept Therapeutics in Q4 2020 and has held it in 24 quarters since.
  • Boston Trust Walden's Corcept Therapeutics position peaked at $70.1M in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Boston Trust Walden's 13F filing for Q3 2026, filed 30 Oct 2026.